ALPPS Procedure in Insufficient Hypertrophy After Portal Vein Embolization (PVE)

被引:27
|
作者
Ulmer, T. F. [1 ]
de Jong, C. [3 ]
Andert, A. [1 ]
Bruners, P. [1 ]
Heidenhain, C. M. [2 ]
Schoening, W. [1 ]
Schmeding, M. [1 ]
Neumann, U. P. [1 ]
机构
[1] Rhein Westfal TH Aachen, Univ Hosp, Dept Gen Visceral & Transplantat Surg, Pauwelsstr 30, D-52074 Aachen, Germany
[2] Sana Hosp Gerresheim, Dept Gen & Visceral Surg, Graeulingerstr 120, D-40625 Dusseldorf, Germany
[3] Rhein Westfal TH Aachen, Univ Hosp, Dept Diagnost & Intervent Radiol, Pauwelsstr 30, D-52074 Aachen, Germany
关键词
ASSOCIATING LIVER PARTITION; 2-STAGE HEPATECTOMY; COLORECTAL METASTASES; MAJOR LIVER; RESECTION; LIGATION; REMNANT; GROWTH; SAFETY; CHEMOTHERAPY;
D O I
10.1007/s00268-016-3662-3
中图分类号
R61 [外科手术学];
学科分类号
摘要
The main limiting factor for major liver resections is the volume and function of the future remnant liver (FLR). Portal vein embolization (PVE) is now standard in most centers for preoperative hypertrophy of FLR. However, it has a failure rate of about 20-30 %. In these cases, the "Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy" (ALPPS) may represent a suitable and possibly the only alternative. We performed a retrospective analysis of nine patients who had ALPPS following an insufficient hypertrophy after PVE. Computed tomography volumetry were performed before and after PVE as well as the first step of ALPPS. Furthermore, complications, 30-day mortality and outcome were analyzed. The FLR volume rose significantly by 77.7 +/- 40.7 % (FLR/TLV: 34.9 +/- 9.7 %) as early as 9 days after the first stage despite insufficient hypertrophy after preoperative portal vein embolization. Major complications (Grade > IIIb) occurred in 33 % of the patients, and 30-day mortality was 11.1 %. The OS at 1 and 2 years was 78 and 44 %. Four patients are presently still alive at a median of 33.4 (range 15-48) months (survival rate 44.4 %). The ALPPS procedure could be a suitable alternative for patients following insufficient PVE or indeed the last chance of a potentially curative treatment in this situation. Nevertheless, the high morbidity and mortality rates and the lack of data on the long-term oncological outcome must also be taken into account.
引用
收藏
页码:250 / 257
页数:8
相关论文
共 50 条
  • [21] ALPPS for hepatocellular carcinoma induces greater hypertrophy compared with portal vein occlusion
    Chia, Daryl
    Yeo, Zachery
    Loh, Stanley
    Iyer, Shridhar
    Bonney, Glenn
    Madhavan, Krishnakumar
    Kow, Alfred
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 414 - 414
  • [22] Simultaneous Portal and Hepatic Vein Embolization achieves better liver hypertrophy and resectability than Portal Vein Embolization alone
    Heil, Jan
    Korenblik, Remon
    Heid, Franziska
    Binkert, Christoph
    Breitenstein, Stefan
    Guiu, Boris
    Hertl, Martin
    Neumann, Ulf P.
    Schnitzbauer, Andreas
    Van der Leij, Christiaan
    Van Dam, Ron
    Schadde, Erik
    SWISS MEDICAL WEEKLY, 2021, 151 : 13 - 13
  • [23] Impaired liver function attenuates liver regeneration and hypertrophy after portal vein embolization
    Yumiko Kageyama
    Takashi Kokudo
    Katsumi Amikura
    Yoshihiro Miyazaki
    Amane Takahashi
    Hirohiko Sakamoto
    World Journal of Hepatology, 2016, (28) : 1200 - 1204
  • [24] Predictive Factors for Hypertrophy of the Future Remnant Liver After Selective Portal Vein Embolization
    Thierry de Baere
    Christophe Teriitehau
    Frederic Deschamps
    Laurence Catherine
    Pramod Rao
    Antoine Hakime
    Anne Auperin
    Diane Goere
    Dominique Elias
    Lukas Hechelhammer
    Annals of Surgical Oncology, 2010, 17 : 2081 - 2089
  • [25] Factors influencing hypertrophy of the left lateral liver lobe after portal vein embolization
    Maciej Malinowski
    Victoria Stary
    Johan F. Lock
    Antje Schulz
    Maximilian Jara
    Daniel Seehofer
    Bernhard Gebauer
    Timm Denecke
    Dominik Geisel
    Peter Neuhaus
    Martin Stockmann
    Langenbeck's Archives of Surgery, 2015, 400 : 237 - 246
  • [26] Predictive Factors for Hypertrophy of the Future Remnant Liver After Selective Portal Vein Embolization
    de Baere, Thierry
    Teriitehau, Christophe
    Deschamps, Frederic
    Catherine, Laurence
    Rao, Pramod
    Hakime, Antoine
    Auperin, Anne
    Goere, Diane
    Elias, Dominique
    Hechelhammer, Lukas
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (08) : 2081 - 2089
  • [27] Factors influencing hypertrophy of the left lateral liver lobe after portal vein embolization
    Malinowski, Maciej
    Stary, Victoria
    Lock, Johan F.
    Schulz, Antje
    Jara, Maximilian
    Seehofer, Daniel
    Gebauer, Bernhard
    Denecke, Timm
    Geisel, Dominik
    Neuhaus, Peter
    Stockmann, Martin
    LANGENBECKS ARCHIVES OF SURGERY, 2015, 400 (02) : 237 - 246
  • [28] Impaired liver function attenuates liver regeneration and hypertrophy after portal vein embolization
    Kageyama, Yumiko
    Kokudo, Takashi
    Amikura, Katsumi
    Miyazaki, Yoshihiro
    Takahashi, Amane
    Sakamoto, Hirohiko
    WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (28) : 1200 - 1204
  • [29] A Comparison of Pitfalls after ALPPS Stage 1 or Portal Vein Embolization in Small-for-Size Setting Hepatectomies
    Schnitzbauer, Andreas A.
    VISCERAL MEDICINE, 2017, 33 (06) : 435 - 441
  • [30] Feasibility of Percutaneous Intrahepatic Split by Microwave Ablation (PISA) After Portal Vein Embolization for Hypertrophy of Future Liver Remnant: The Radiological Stage-1 ALPPS
    Lunardi, Alessandro
    Cervelli, Rosa
    Volterrani, Duccio
    Vitali, Saverio
    Lombardo, Carlo
    Lorenzoni, Giulia
    Crocetti, Laura
    Bargellini, Irene
    Campani, Daniela
    Pollina, Luca Emanuele
    Cioni, Roberto
    Caramella, Davide
    Boggi, Ugo
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 41 (05) : 789 - 798